Want to see SNY full AI Analyst Report?
SNY Stock Chart & Stats
$46.02
$1.02(2.35%)
At close: 4:00 PM EDT
$46.02
$1.02(2.35%)
Day’s Range― - ―
52-Week Range$39.07 - $52.68
Previous CloseN/A
Volume449.65K
Average Volume (3M)3.09M
Market Cap
$96.91B
Enterprise Value$122.96B
Total Cash (Recent Filing)$6.35B
Total Debt (Recent Filing)$23.58B
Price to Earnings (P/E)22.0
Beta0.42
Next Earnings
Oct 30, 2026EPS Estimate
1.55Next Dividend Ex-DateN/A
Dividend Yield5.96%
Share Statistics
EPS (TTM)0.48
Shares Outstanding2,415,546,900
10 Day Avg. Volume3,598,554
30 Day Avg. Volume3,091,162
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.15
P/FCF Ratio9.92
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit3.44
Enterprise Value/Ebitda8.32
Forecast
1Y Price Target
$59.50Price Target Upside29.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.85
Revenue Forecast (FY)$56.05B
Bulls Say, Bears Say
Bulls Say
Steady Revenue ExpansionSanofi has delivered several years of revenue expansion, with growth accelerating in 2025. Sustained sales increases indicate continued demand across its medicines and vaccines portfolio, supporting investment in research, launches, and commercial capabilities over the next several quarters.
Conservative Balance SheetA substantial equity base and moderate leverage provide Sanofi with financial flexibility relative to its scale. This supports continued research investment, portfolio development, and potential strategic actions while reducing the balance-sheet pressure that can constrain pharmaceutical companies during weaker operating periods.
Expanded Vaccine Market AccessThe expanded MenQuadfi indication broadens Sanofi’s addressable population and aligns the vaccine with routine European infant immunization schedules. Broader eligibility and demonstrated compatibility with pediatric vaccines can strengthen product relevance and support durable vaccine-market positioning.
Bears Say
Operating Margin PressureDeclining operating profit while revenue increases suggests that incremental sales are not translating fully into operating earnings. If this pattern persists, higher costs or an unfavorable mix could limit earnings growth and reduce the financial benefit of Sanofi’s otherwise expanding top line.
Volatile Free Cash FlowPositive cash generation is a strength, but pronounced year-to-year volatility makes internal funding less predictable. Weaker earnings-to-cash conversion in 2024 could complicate planning for research, acquisitions, dividends, or debt reduction if similar fluctuations recur.
Uneven Earnings ProfileThe uneven multi-year earnings pattern tempers the quality of Sanofi’s growth and makes future profitability less predictable than its revenue trend. Volatile earnings can make capital allocation and performance assessment more difficult even when the underlying business continues to expand.
Sanofi News
SNY FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was $39.07 and its highest was $52.68 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $96.91B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 30, 2026 which is in 10 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 30, 2026. The company reported $1.202 earnings per share for the quarter, beating the consensus estimate of $1.088 by $0.114.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of $2.419 which represents an annual dividend yield of 5.96%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.55.
How many shares outstanding does Sanofi have?
Sanofi has 2,415,546,900 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $1.202 in its last earnings report, beating expectations of $1.088. Following the earnings report the stock price went down -4.37%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in SNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanofi Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.50 (29.29% Upside)
$59.50 (29.29% Upside)
Blogger Sentiment
Bullish
SNY Sentiment 89%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.57%
12-Months-Change
Fundamentals
Return on Equity
5.52%
Trailing 12-Months
Asset Growth
0.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sanofi
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
SNY Company Deck
SNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top-line growth (9.9% FY, 13.3% Q4), robust launch performance (EUR 5.7bn from new products), significant pipeline delivery and regulatory progress, improved margins and free cash flow, plus strategic BD/M&A activity. Notable challenges include a Phase III failure for tolebrutinib, a safety case in the amlitelimab program that will require monitoring, decreased Regeneron R&D reimbursements (offset partly by higher royalties), and some uncertainty in the U.S. vaccine schedule and vaccine sales in 2026. Overall, positives (growth, profitability, launches, pipeline replenishment and balance sheet flexibility) outweigh the lowlights, though execution and regulatory/safety risks remain important to monitor.View all SNY earnings summariesSNY Stock 12 Month Forecast
Average Price Target
$59.50
▲(29.29% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.66% Mutual Funds
0.12% Other Institutional Investors
97.95% Public Companies and
Individual Investors